Juvenile Idiopathic Arthritis Clinical Trial
Official title:
Oxidation Rates of the Different Substrates During Exercise in Children and Adolescents With Juvenile Idiopathic Arthritis. Case-control Study and Cases Treated / Cases Not Treated With Anti-TNFα
During exercise, energy comes mainly from carbohydrates and lipids. The relative
contribution of lipids and glucose as energy substrates to exercise depends on the
parameters of the exercise (duration, intensity and level of training) and the physiological
conditions of the subject.
Inflammatory diseases such as juvenile idiopathic arthritis (JIA) are treated, for the most
severe forms, by biotherapies. These treatments target certain pro-inflammatory cytokines
including TNFα. In adults with rheumatoid arthritis several studies have shown that
treatment with anti-TNFα increases insulin sensitivity. There is no data on the oxidation of
energy substrates during exercise in children and adolescents with AJI, nor on the impact of
anti-TNFα treatments on the oxidation of energetic substrates in children.
Investigators hypothesize that, compared to healthy children, children with JIA should
exhibit altered oxidation of energy substrates at rest and submaximal physical exercise due
to physical deconditioning and inflammation. In addition, those treated with anti-TNFα
should have an oxidation profile of energy substrates at exercise different from that of
patients not treated with anti-TNFα. Investigators also hypothesize that anti-TNFα
treatments modify the contribution of energy chains (aerobic, anaerobic and anaerobic
alactic) during the exercise.
Annual evaluation by Lipoxmax test and Wingate anaerobic test (WAnT) during 3 years or until
the transition from pediatric to adult care.
For healthy volunteer, only one lipaxmax and Wingate test.
;
Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02776735 -
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
|
Phase 2 | |
Active, not recruiting |
NCT03092427 -
Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)
|
N/A | |
Not yet recruiting |
NCT05545098 -
MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA
|
||
Not yet recruiting |
NCT03833609 -
Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis
|
N/A | |
Completed |
NCT02524340 -
Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference
|
||
Recruiting |
NCT01434082 -
Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis
|
N/A | |
Completed |
NCT04671524 -
The Effect of Improvement in Function on Foot Pressure, Balance and Gait in Children With Upper Extremity Affected
|
N/A | |
Recruiting |
NCT04167488 -
Assessment of Physical Activity Among Juvenile Idiopathic Arthritis Children Performed With Actigraphy
|
N/A | |
Recruiting |
NCT04205500 -
Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis
|
N/A | |
Terminated |
NCT01694264 -
Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα
|
Phase 3 | |
Completed |
NCT02824978 -
Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?
|
||
Active, not recruiting |
NCT03841357 -
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
|
Phase 3 | |
Completed |
NCT03833271 -
The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary
|
Early Phase 1 | |
Completed |
NCT01455701 -
A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 1 | |
Completed |
NCT05031104 -
Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis
|
N/A | |
Not yet recruiting |
NCT01436019 -
Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis
|
N/A | |
Recruiting |
NCT05609630 -
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
|
Phase 3 | |
Recruiting |
NCT05696340 -
Access to Pediatric Rheumatology Centers for JIA Patients: Factors Associated With Time to Access Pediatric Rheumatology Centers
|
||
Recruiting |
NCT05545839 -
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
|
N/A | |
Completed |
NCT05436301 -
Turkish Validity and Reliability of Pain Catastrophizing Scale-Child (PCS-C)
|